NT$259.50
+
NT$2.50 (0.97%)
End-of-day quote: 05/17/2024
TPEX:3218
Universal Vision Biotechnology Annual Report
| Year | Year | 2023 | 2022 | 2021 | 2020 | 2019 | 2013 | 2008 | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Rev. | Revenue |
|
NT$4.08B | NT$3.49B | NT$2.63B | NT$2.05B | NT$1.42B | NT$916.31M | NT$546.23M | |
| GM % | Gross Margin % |
|
59.98% | 61.24% | 62.18% | 61.72% | 57.58% | 56.41% | 42.37% | |
| OM | Operating Margin |
|
32.14% | 30.94% | 29.20% | 29.05% | 17.41% | 9.79% | -7.81% | |
| EPS | Earnings Per Share |
|
NT$0.00 | NT$12.34 | NT$10.02 | NT$7.02 | NT$5.71 | NT$2.80 | NT$1.18 | NT$-0.66 |
| Div. | Dividends |
|
NT$7.00 | NT$5.43 | NT$4.49 | NT$3.77 | NT$1.80 | NT$0.90 | NT$0.00 | |
| PR % | Payout Ratio % |
|
56.73% | 54.19% | 63.96% | 66.02% | 64.29% | 76.27% | 0 | |
| Sha. | Shares |
|
84.73m | 84.72m | 76.12m | 76.12m | 76.12m | 66.12m | 39.07m | |
| OCF | Operating Cash Flow |
|
NT$1.55B | NT$1.27B | NT$911.77M | NT$827.08M | NT$419.18M | NT$191.69M | NT$92.94M | |
| FCF | Free Cash Flow |
|
NT$1.11B | NT$792.17M | NT$587.33M | NT$531.93M | NT$183.99M | NT$96.86M | NT$-17.54M | |
| FCFS | Free Cash Flow Per Share |
|
NT$12.74 | NT$9.15 | NT$7.66 | NT$6.94 | NT$2.36 | NT$1.36 | NT$-0.44 |
